Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-C motif chemokine ligand 22 (CCL22)
- Target
- CCL22
- Molecular classification
- Chemokine, Cytokine, Secreted protein (ligand for chemokine receptors such as CCR4), Family: CC chemokine family (two adjacent cysteines motif), Other: Signaling molecule
01
Overview
C-C motif chemokine ligand 22 (CCL22) is a small secreted protein of the CC chemokine family predominantly produced by dendritic cells and macrophages. It acts as a chemoattractant, particularly for memory T cells, natural killer cells, and dendritic cells, by binding to the CC chemokine receptor 4 (CCR4). The protein plays a central role in immune cell trafficking, the regulation of inflammatory responses, and is involved in the pathogenesis of various immune-related diseases, including cancer, allergies, and autoimmune disorders. It is a common subject of research in immunology and targeted therapy development.
- Other names
- CCL22MDC (Macrophage-derived chemokine)ABCD-1DC/B-CKSCYA22STCP-1A-152E5.1DCBCKMacrophage Chemotactic Protein 1
02
Mechanism of action
Chemokine receptor antagonism (drugs interfere with CCL22 binding to CCR4, reducing immune cell recruitment); Immune modulation (by altering CCL22 signaling pathways, drugs can impact inflammatory responses)
03
Biological functions
Immune response (regulation and recruitment of immune cells)Signal transduction (through interaction with CCR4)Cell migration/chemotaxis (attracts T cells, dendritic cells, and other leukocytes)Inflammation (modulates inflammatory responses, especially in allergic and autoimmune conditions)
04
Disease associations
Cancer (associated with tumor microenvironment and immune cell recruitment)Inflammation (chronic inflammatory diseases)Infection (chemotactic for immune cells in infection settings)Other (modulation of allergy and autoimmune diseases)
05
Safety considerations
Therapeutic challenges include potential immunosuppression, off-target effects (altering recruitment of regulatory T cells or other immune cells), and risk of infections due to modulation of immune signaling
06
Interacting drugs
Specific therapeutics targeting CCL22 or its receptor CCR4 include investigational agents like CCR4 antagonists; CCL22 as a direct target is less common than its receptor CCR4. No approved drugs directly target CCL22, but it is implicated in the development and testing of therapies modulating chemokine signaling
07
Biomarkers
CCL22 protein levels may serve as biomarkers for inflammatory diseases, cancer progression, and immune status in certain therapeutic contexts
Beyond the preview
Go deeper on C-C motif chemokine ligand 22 (CCL22).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-C motif chemokine ligand 22 (CCL22).